Can Cancer Patients Donate Organs After Death?

Organs from people who had cancer can be, and regularly are, transplanted into recipients after the donor’s death. The practice is more common than most people realize, though it depends heavily on the type, stage, and location of the cancer the donor had. A study of more than 30,000 transplants in the United Kingdom found that donor-derived cancer occurred in just 0.06 percent of recipients, and transplant teams use detailed risk frameworks to decide which organs are safe to use.

How Transplant Teams Categorize the Risk

Not all cancers carry the same risk of being passed from a deceased donor to a recipient. Transplant organizations sort donor cancers into risk tiers based on how likely the cancer is to travel with the transplanted organ. These categories range from minimal risk (where transmission is essentially unheard of) to high risk (where the chance exceeds roughly one in ten). The framework is not based on a single large trial but rather draws on decades of transplant registry data and individual case reports, which means the estimates are educated approximations rather than precise statistics.

At the low end, cancers that tend to stay localized and are caught early pose very little threat to recipients. At the high end, cancers known for spreading aggressively through the bloodstream are treated with far more caution. Malignant melanoma and choriocarcinoma, for example, are classified as high-risk because they have a documented transmission rate above 10 percent.¹ The classification system also acknowledges its own limitations. As one guideline document put it, no high-level evidence exists to establish true transmission frequency estimates, and the figures are meant to provide a basis for different levels of concern rather than definitive answers.²

This means transplant teams make judgment calls. A donor with a history of a small, low-grade skin cancer treated five years ago is evaluated very differently from one who died with active metastatic disease. The risk framework gives clinicians a shared vocabulary, but the final decision is always individualized.

Brain Tumors Are the Most Common Cancer in Organ Donors

People who die of primary brain tumors represent a uniquely important group in organ donation. Because these patients frequently progress to brain death while the rest of their organs remain healthy, they are medically ideal candidates for donation. At the same time, transplant teams historically worried that tumor cells might hitch a ride on a donated organ. The evidence has been reassuring.

A large analysis published in JAMA Surgery tracked recipients who received organs from donors with primary brain tumors. Among 83 cancers that developed in those recipients over a median follow-up of about six years, none matched the type of cancer the donor had. Transplant survival in these recipients was equivalent to that of matched controls who received organs from donors without brain tumors.³ A separate analysis of UK registry data reached a similar conclusion: no transmission of donor brain cancer occurred, and the authors argued that organs from patients dying of primary brain tumors, including high-grade ones, should be considered for transplantation.⁴

Despite this track record, utilization rates for organs from donors with high-grade brain tumors remain lower than for matched donors without cancer.³ That gap between evidence and practice represents organs that could be saving lives but are being turned down. Recent reviews have noted that brain tumors were historically placed in a greater-than-10-percent risk category but have since been reclassified to around 2.2 percent risk, a figure that many transplant professionals feel should change how aggressively these organs are offered.⁵

How Donors Are Screened Before Organs Are Accepted

The screening process for deceased donors is multilayered and fast-moving, since organs deteriorate quickly after death. Teams review the donor’s medical history, imaging, and lab results. If anything raises suspicion, the investigation gets more invasive. One established protocol, developed in Verona and used for over 15 years, employs a two-step process: an initial screen of clinical, radiological, and lab findings, followed by hands-on assessment during the organ retrieval surgery itself if anything looks concerning.⁶

Frozen-section biopsies, where tissue samples are rapidly analyzed by a pathologist while the surgical team waits, play a crucial role. In one series of 60 pretransplant biopsies, five transplants were cancelled because of malignancy findings. The technique is not perfect: the same series documented one false-positive and one false-negative cancer result, illustrating that even on-the-spot pathology has limits.⁷ Still, it catches the majority of unexpected tumors before an organ reaches a recipient.

The speed pressure is real. Transplant teams sometimes have only hours to decide whether an organ is usable, and the tools they rely on, while good, are designed for rapid assessment rather than exhaustive oncologic workup. This is part of why the risk framework described earlier matters so much: it gives teams a pre-agreed decision tree rather than forcing them to reason from scratch at 3 a.m.

Kidneys With Small Tumors Can Be Transplanted After the Tumor Is Removed

One of the more creative strategies in transplant medicine involves kidneys that have small renal masses. Rather than discard a kidney because it has a tumor, surgeons can remove the tumor from the kidney on the back table before implanting it. This approach, sometimes called ex vivo tumor excision, takes advantage of the fact that small, low-stage kidney cancers have a favorable natural history and, if completely excised, carry a low risk of recurrence in the recipient.

A systematic review identified 226 patients across 32 studies who received kidneys from donors with malignant renal masses. The average tumor size was about 13 millimeters, and roughly four in five were low-grade. Recurrence occurred in about 2.7 percent of recipients, with the average time to recurrence being around three years. One-year overall survival for recipients of living-donor grafts was about 96 percent, dropping to about 75 percent at five years.⁸ A separate review of 147 tumor-excised kidneys found that the vast majority of tumors were small renal cell carcinomas, almost all of which were stage T1a.⁹

Early case series supported the concept. Reports to a transplant tumor registry found that among 14 cases where kidneys with excised tumors were intentionally transplanted (with an average tumor diameter of 2 centimeters), no cancers were detected in recipients over a mean follow-up of nearly six years.¹⁰ The complication rate is not trivial, however. The systematic review noted a serious complication rate of about 22 percent, which means this approach is generally reserved for recipients who would otherwise face very long wait times or who are running out of dialysis options.⁸

Corneas and Tissues Follow Different Rules

Organ donation gets most of the attention, but tissue donation, including corneas, skin, bone, and heart valves, follows its own set of guidelines for donors with cancer. Corneal transplantation is particularly permissive. Some eye banks accept corneas from cadavers with active cancer, including both solid tumors and blood cancers, because the cornea has no blood supply. Without a blood vessel network to carry tumor cells into the tissue, the chance that cancer could set up shop in a transplanted cornea is considered extremely low.¹¹

Other tissues occupy a gray area. Bone and tendons are processed and sterilized before use, which provides some protection. Skin grafts from donors with certain cancers may be accepted for burn patients whose immediate survival depends on wound coverage, even if there is some theoretical risk. The general principle is that avascular tissues (those without a direct blood supply) are safer than vascularized organs, because cancer cells overwhelmingly spread through the bloodstream or lymphatic system. This means a donor whose cancer makes their liver or lungs unsuitable for transplant might still provide corneas or processed bone that saves someone else’s sight or mobility.

What Happens If Cancer Is Transmitted

Donor-transmitted cancer is rare, but it does happen. The UK data mentioned earlier found 15 cases of donor-transmitted cancer among more than 30,000 transplants, with kidney cancer and lung cancer being the most common types transmitted.⁵ When it does occur, the treatment approach is drastically different from typical cancer care.

The transplanted organ is essentially foreign tissue being kept alive by immunosuppressive drugs. If a cancer transmitted via that organ is discovered, the first step is usually stopping immunosuppression. With the immune system no longer suppressed, the recipient’s body often attacks both the transplanted organ and the cancer growing in it. In some cases, the organ has to be surgically removed. One reported case involved a kidney recipient who developed malignant melanoma transmitted from the donor. Immunosuppression was stopped and targeted cancer therapy was started, but the resulting rejection was severe enough to require dialysis and urgent removal of the transplanted kidney.¹²

This is obviously a terrible outcome for the patient, who loses both the kidney and their freedom from dialysis. But in some cases, removing the organ and stopping immunosuppression is enough for the body to clear the transmitted cancer entirely. The immune system, once it is no longer being held back, can sometimes handle a cancer that was only thriving because of the drugs. This does not always work, and some transmitted cancers are fatal, but the existence of this “escape hatch” is part of why transplant teams are willing to accept carefully stratified risks from donors with certain cancer histories.

Why Recipients Are Asked to Accept the Risk

Transplant teams do not make these decisions in a vacuum. When an organ comes from a donor with any cancer history, the intended recipient is informed. The conversation is a balancing act: on one side is the small risk that the organ carries hidden cancer cells, and on the other is the very real risk of staying on the waiting list. In many countries, patients die every day while waiting for organs. A person on dialysis facing a three-to-five-year wait for a kidney from a “perfect” donor may rationally choose to accept a kidney from a donor whose cancer history carries a slightly elevated risk.

Guidelines increasingly emphasize that this decision should be fully individualized and that informed consent is mandatory whenever the risks exceed standard expectations.⁵ The framing matters. Telling someone “this organ may carry a 1 percent chance of transmitting cancer” sounds alarming in isolation. Telling them “you have a 20 percent chance of dying on the waiting list within two years” puts the first number in context. Transplant professionals generally try to present both sides so the recipient can make a genuinely informed choice.

There is also an ethical dimension around the donor. Some families of cancer patients are told their loved one cannot donate, full stop, when the reality is more nuanced. A person dying of a glioblastoma might have perfectly healthy kidneys, and a blanket refusal wastes that gift. As organ procurement organizations refine their criteria, the trend is toward accepting more donors with cancer histories, not fewer, because the evidence base increasingly supports it.

The Donor Shortage Driving Policy Changes

The backdrop to all of this is a chronic, worsening shortage of donor organs. Waiting lists continue to grow, and the average age of potential donors keeps rising, which means more potential donors have cancer in their medical histories. This intersection of demographics and demand has pushed transplant communities worldwide to reconsider how conservatively they define “acceptable” donors.

Reviews of the current landscape have pointed to a persistent sense of missed opportunities. Organs from donors with cancers that retrospectively turned out to pose minimal transmission risk were declined, and the recipients who could have received them either waited longer or died on the list.⁵ Current classification systems evolved from case reports and registry data rather than from prospective clinical trials, which means they cannot cover every scenario. The guidelines acknowledge this limitation openly, and many transplant centers supplement them with local expertise and multidisciplinary review.¹³

Different countries handle the question differently. Some rely on centralized registries that track every donor-transmitted cancer event, feeding data back into policy. Others operate with looser oversight and more clinician discretion. The general direction is convergent, though: as data accumulates showing that many cancers pose little transmission risk, policies are expanding to include donors who would have been rejected a decade ago. The evidence from brain tumor donors, from small renal masses, and from long-term follow-up studies all point the same way. The field is learning that the question is not whether cancer patients can donate after death, but how to identify which organs from which cancer patients are safe enough to save someone’s life.

Cancers That Remain Off-Limits

For all the progress in expanding donor eligibility, some cancers are still considered too dangerous. Active metastatic disease of almost any kind rules out organ donation. Melanoma and choriocarcinoma remain in the highest risk category, with transmission rates estimated above 10 percent.¹ Melanoma is especially concerning because it can remain dormant for years and then spread explosively, and because it is notoriously capable of seeding distant organs with microscopic deposits that standard screening may miss. The case of the kidney recipient who developed donor-transmitted melanoma underscores why transplant teams treat that diagnosis with extreme caution.¹²

Blood cancers like leukemia and lymphoma also generally disqualify organ donation, though even here there are exceptions under investigation. The challenge with hematologic cancers is that malignant cells circulate freely throughout the body, making it nearly impossible to guarantee that any organ is free of them. The field has not closed the door entirely on these cases, but they require an especially rigorous case-by-case evaluation, and most transplant centers remain conservative.

A useful mental model is that the farther a cancer has spread from its site of origin, and the more it relies on the bloodstream to do so, the more dangerous it is as a potential hitchhiker on a donated organ. Cancers that stay put, like most primary brain tumors or early-stage kidney tumors, are far less threatening than those with a documented tendency to seed distant organs.

The Role of Immunosuppression in Transmission Risk

One reason donor-transmitted cancer is a concern at all is that transplant recipients take immunosuppressive drugs for the rest of their lives. These drugs prevent the immune system from attacking the transplanted organ, but they also weaken the body’s ability to detect and destroy abnormal cells, including cancer cells. A healthy immune system might eliminate a handful of stray tumor cells that arrived with a transplanted organ. A suppressed immune system is far less likely to catch them.

This is the same reason transplant recipients, regardless of whether their donor had cancer, develop new cancers at higher rates than the general population. The immunosuppression they need to keep their transplant functioning comes at the cost of reduced cancer surveillance by their own immune system. When a donor-transmitted cancer does take hold, the option to stop immunosuppression and let the immune system attack the foreign cancer cells exists precisely because those cells are, genetically, someone else’s tissue. The recipient’s immune system can recognize them as foreign once the drugs are no longer holding it back. This approach does not apply to cancers that arise independently in the recipient after transplant, because those come from the recipient’s own cells and are not foreign in the same way.

The interplay between immunosuppression and transmission risk also explains why the window of danger is widest in the first months after transplant, when drug doses tend to be highest. As doses taper over time, the immune system regains some of its surveillance capacity, and the risk that a small cluster of donor tumor cells will establish itself diminishes.